Eli Lilly 2012 Annual Report Download - page 15

Download and view the complete annual report

Please find page 15 of the 2012 Eli Lilly annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 164

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164

3
Part I
Item 1. Business
Eli Lilly and Company (the “company” or “registrant” or "Lilly") was incorporated in 1901 in Indiana to succeed
to the drug manufacturing business founded in Indianapolis, Indiana, in 1876 by Colonel Eli Lilly. We discover,
develop, manufacture, and market products in two business segments—human pharmaceutical products and
animal health products.
The mission of our human pharmaceutical business is to make medicines that help people live longer,
healthier, more active lives. Our strategy is to create value for all our stakeholders by accelerating the flow of
innovative new medicines that provide improved outcomes for individual patients. Most of the products we sell
today were discovered or developed by our own scientists, and our success depends to a great extent on our
ability to continue to discover, develop, and bring to market innovative new medicines.
Our animal health business, operating through the Elanco Animal Health division, develops, manufactures,
and markets products for both food and companion animals.
We manufacture and distribute our products through facilities in the United States, Puerto Rico, and 11 other
countries. Our products are sold in approximately 130 countries.
Human Pharmaceutical Products
Our human pharmaceutical products include:
Neuroscience products, our largest-selling product group, including:
• Cymbalta®, for the treatment of major depressive disorder, diabetic peripheral neuropathic pain,
generalized anxiety disorder, and in the U.S. for the management of fibromyalgia and of chronic
musculoskeletal pain due to chronic low back pain or chronic pain due to osteoarthritis
• Zyprexa®, for the treatment of schizophrenia, acute mixed or manic episodes associated with bipolar I
disorder, and bipolar maintenance
• Strattera®, for the treatment of attention-deficit hyperactivity disorder in children, adolescents, and in
the U.S., in adults
• Prozac®, for the treatment of major depressive disorder, obsessive-compulsive disorder, bulimia
nervosa, and panic disorder
• Symbyax®, for the treatment of bipolar depression and treatment-resistant depression
• Amyvid™, a radioactive diagnostic agent approved in 2012 in the U.S. and 2013 in the European Union
(EU) for positron emission tomography (PET) imaging of beta-amyloid neuritic plaques in the brains of
adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other
causes of cognitive decline.
Endocrinology products, including:
• Humalog®, Humalog Mix 75/25™, and Humalog Mix 50/50™, for the treatment of diabetes
• Humulin®, for the treatment of diabetes
• Byetta®, for the treatment of type 2 diabetes
• Bydureon®, for the treatment of type 2 diabetes (see “Human Pharmaceutical Marketing
Collaborations” below for information about the termination of our collaboration with Amylin
Pharmaceuticals for Byetta and Bydureon)
• Tradjenta®, for the treatment of type 2 diabetes
• Jentadueto®, a combination tablet of Tradjenta and metformin hydrochloride for use in the treatment
of type 2 diabetes